NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $675,709 | -55.7% | 85,968 | -43.7% | 0.00% | – |
| Q2 2023 | $1,525,133 | -18.7% | 152,666 | -27.7% | 0.00% | – |
| Q1 2023 | $1,876,255 | -35.0% | 211,290 | -19.6% | 0.00% | – |
| Q4 2022 | $2,885,621 | +1.0% | 262,807 | +19.9% | 0.00% | – |
| Q3 2022 | $2,856,000 | +101.1% | 219,179 | +95.5% | 0.00% | – |
| Q2 2022 | $1,420,000 | -66.1% | 112,100 | -62.5% | 0.00% | -100.0% |
| Q1 2022 | $4,187,000 | +128.4% | 298,883 | +372.3% | 0.00% | – |
| Q4 2021 | $1,833,000 | +17.4% | 63,279 | +21.4% | 0.00% | – |
| Q3 2021 | $1,561,000 | +16.1% | 52,106 | +2.8% | 0.00% | – |
| Q2 2021 | $1,344,000 | +345.0% | 50,671 | +451.7% | 0.00% | – |
| Q4 2020 | $302,000 | -96.5% | 9,184 | -96.3% | 0.00% | -100.0% |
| Q3 2020 | $8,560,000 | – | 245,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |